Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada. Cardiome Pharma Corp., a life sciences company, focuses on developing drugs to treat or prevent cardiovascular diseases. Its product Vernakalant (iv), which has completed Phase III (ACT 4) and in Phase III (European Comparator) trial is used for the treatment of atrial fibrillation; Vernakalant (oral) that has completed Phase IIa Pilot and Phase IIb study is used for atrial fibrillation; GED-aPC, an ongoing Phase I study product for multiple disease states; and Artesian Programs, which is in pre-clinical studies to attenuate the deleterious effects of the excessive neurohormonal activation that occurs in diseases of cardiac dysfunction.

XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

PharmaNet, a global, drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. In addition, PharmaNet offers technology tools for managing clinical trial data.

Marligen Biosciences is where researchers go again and again for testing products and services. The company makes nucleic acid purification systems, genetic analysis assays, and other genomics research supplies. Its nucleic acid purification systems include rapid plasma purification systems which are used for isolation DNA so it can mapped, cloned, amplified, labeled, and sequenced. Its genetic analysis assays are sold under the Signet brand name and can screen for certain classes of DNA or be tailored to the researchers needs. Marlingen was acquired by another genetic services provider, OriGene, in 2009.

AMAG Pharmaceuticals, Inc. company was founded in 1981 and is based in Lexington, Massachusetts. AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic agent for the treatment of iron deficiency anemia and used as a diagnostic agent for vascular enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease; and GastroMARK used for delineating the bowel in MRI. AMAG Pharmaceuticals products also include Combidex, an investigational functional molecular imaging agent.

Established in 2004, Merrion operates offices in North Carolina and Ireland. Merrion Pharmaceuticals wants to make complicated drug dosing regimens easier to swallow. A specialty pharmaceutical firm, Merrion develops (independently and in collaboration with other drug companies) oral drugs to replace already-approved injectable-only medicines. Using its patented drug delivery technologies, Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) improves the absorption of drugs into the blood stream. Its Gastrointestinal Retention System (GIRES) helps the stomach retain drugs, allowing for their extended, controlled release. The company has four candidates in the development pipeline.

Synarc, Inc. provides medical image-analysis, subject-recruitment, and biochemical-marker services to execute clinical trials for life-science industry clients. The company’s services include protocol design, imaging-site selection and training, imaging equipment monitoring, imaging quality assurance, centralized image analysis, centralized biochemical-marker assays, data management, project management, reporting and medical writing, and regulatory consulting and liaison with global agencies. It offers its services in various therapeutic areas, including cardiology, metabolic disorders, neurovascular diseases, neurology, oncology, orthopedics, osteoarthritis, osteoporosis, and rheumatoid arthritis. Synarc also operates clinical research centers in Europe, China, and Brazil. The company, formerly known as Advanced Imaging Research Services, Inc., was founded in 1998 and is based in San Francisco, California with additional offices in the United States, Denmark, France, Germany, Poland, the Czech Republic, Romania, Lithuania, Estonia, Brazil, Hong Kong, and China.

Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

he UK-based company makes non-invasive diagnostic tests, which are marketed under the foodSCAN and First Step Food Intolerance Test brand name, used to determine which foods a patient may be allergic to. It also provides customers with its LiverCheck brand tests, which are used to test the health of your liver, and Body ID Plan, which offers a diet plan from an analysis of a blood sample. Founded in 1982, YORKTEST Laboratories Ltd. makes its home health tests available for sale on its Web site.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.